Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BBI Group
While COVID-19 testing capacity rises slowly the in UK, the scientific community is pressing to develop the range of test types to get the numbers up further to secure sustainable control of the disease.
The COVID-19 antibody tests that so far have gone through the validation process have not proven accurate enough to be rolled out for public use, says the UK. A new rapid test consortium is working on a solution.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced June-July 2015.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- BBI Diagnostics Group PLC
- Maine Biotechnology Services, Inc.